No Data
No Data
Reported Saturday, Johnson & Johnson's TAR-200 Monotherapy Demonstrates Strong Early Efficacy In BCG-Unresponsive Bladder Cancer, Achieving Over 80% Disease-Free Survival
Express News | Johnson & Johnson : HSBC Raises Target Price to $184 From $180
Jim Cramer Says You Should Buy Johnson & Johnson (JNJ), Thinks Talc Problems 'Behind It'
J&J Posts Mid-stage Trial Data for Chemotherapy Releasing System in Bladder Cancer
Express News | Johnson & Johnson - Initiates FDA Application for Tar-200 Under Rtor Program
Express News | Johnson & Johnson - Phase 2B Study: 82% Achieve Complete Response, 52.9% Cancer-Free at One Year
loading...